J Korean Pediatr Cardiol Soc.
2007 Sep;11(3):149-150.
Indications, Efficacy and Safety of Anti-RS Virus Monoclonal Antibody Palivizumab (Synagis) for Pediatric Patients With Congenital Heart Diseases
- Affiliations
-
- 1Division of Pediatric Cardiology, Heart Center, Department of Pediatrics, Head, Toho University School of Medicine, Tokyo, Japan.
- 2Head, Scientific Committee, and Council member, of the Japanese Society of Pediatric Cardiology and Cardiac Surgery.
Abstract
- No abstract available.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
- Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey
- Effect of Synagis(R) (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants
- Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009
- Analysis of Palivizumab Prophylaxis in Patients with Acute Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus
